# Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

> **NCT01616524** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 880 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **BIOLOGICAL:** Pegylated interferon lambda (pegIFNλ)
- **BIOLOGICAL:** Pegylated interferon lambda (pegIFNλ)
- **BIOLOGICAL:** Pegylated interferon alfa-2a (pegIFNα-2a)
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin
- **DRUG:** Daclatasvir
- **DRUG:** Placebo matching Daclatasvir

## Key facts

- **NCT ID:** NCT01616524
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-09
- **Target enrollment:** 880 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01616524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01616524, "Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01616524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*